Sensus Healthcare Inc.
SRTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SRTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SRTS
Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological conditions, with a recent cash position of $15.2M as of 2026-06-30 and ongoing revenue generation from equipment sales.
Key risk: Cash burn and losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological conditions, with a recent cash position of $15.2M as of 2026-06-30 and ongoing revenue generation from equipment sales.
- Sensus Healthcare is a medical device company providing non-invasive, cost-effective treatments for both oncological and non-oncological conditions [sec_mda · as of 2025-11-12].
- Cash and cash equivalents were $18.3M as of March 31, 2026, decreasing from $22.1M at December 31, 2025 [sec_mda · as of 2026-05-13].
- Latest reported financials (as of 2026-06-30) show cash & equivalents of $15.2M, total revenue of $2.3M, and net income of -$8.7M [sec].
- The company manages its business globally within one reportable segment [sec_mda · as of 2025-11-12].
- For the nine months ended September 30, 2025, revenues were $22.5M compared to $28.7M in the same period of 2024 [sec_mda · as of 2025-11-12].
What works
- The company believes it has sufficient liquidity from cash equivalents, borrowing capacity under its existing line of credit, and access to capital resources to meet operating needs for the next 12 months [sec_mda · as of 2025-08-12].
- Sensus has a revolving credit facility with Comerica Bank, providing additional financial flexibility [sec_mda · as of 2026-03-04].
- Revenue generation from equipment sales in the ordinary course of business provides ongoing funding [sec_mda · as of 2025-08-12].
What to weigh
- Cash and cash equivalents decreased by $3.8M from December 31, 2025 to March 31, 2026, indicating cash burn [sec_mda · as of 2026-05-13].
- Net income was -$8.7M for the latest reported period as of 2026-06-30, reflecting ongoing losses [sec].
- Accounts receivable decreased by $2.4M from December 31, 2025 to March 31, 2026, primarily due to decreased sales and concentration of sales to a historically large customer [sec_mda · as of 2026-05-13].
- Revenues for the nine months ended September 30, 2025 declined to $22.5M from $28.7M in the prior year period [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Cash and cash equivalents were $18.3M as of March 31, 2026.
“Cash and cash equivalents were $18.3 million at March 31, 2026 compared to $22.1 million at December 31, 2025”
SEC MD&A · May 13, 2026
The company has a revolving credit facility with Comerica Bank.
“revolving credit facility with Comerica Bank”
SEC MD&A · March 4, 2026
Risks & what to watch (4)›
Key risks
- Cash burn and losses — Net loss of $8.7M as of 2026-06-30 and decreasing cash reserves indicate ongoing cash burn [sec].
- Revenue decline — Revenues decreased from $28.7M to $22.5M for the nine months ended September 30, 2025 [sec_mda · as of 2025-11-12].
- Customer concentration — Decrease in accounts receivable due to concentration of sales to a historically large customer [sec_mda · as of 2026-05-13].
- Liquidity dependence on credit — Relies on borrowing capacity under existing line of credit for liquidity [sec_mda · as of 2026-03-04].
What to watch
- Monitor future revenue trends and ability to reverse the decline seen in 2025 [sec_mda · as of 2025-11-12].
- Watch cash burn rate and whether the company can achieve profitability given net losses [sec].
- Track any updates on customer concentration and diversification efforts [sec_mda · as of 2026-05-13].
- Observe any changes in the revolving credit facility or access to capital [sec_mda · as of 2026-03-04].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Sensus Healthcare Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sensus Healthcare Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
21.0 months
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$12.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,296,450 | $5.2M |
| dimensional fund advisors lp | 387,392 | $1.5M |
| renaissance technologies llc | 252,234 | $1.0M |
| geode capital management, llc | 165,550 | $659K |
| meros investment management, lp | 152,418 | $607K |
| north star investment management corp. | 125,586 | $500K |
| bank of new york mellon corp | 100,410 | $400K |
| vanguard fiduciary trust co | 75,730 | $301K |
| blackrock, inc. | 71,167 | $283K |
| state street corp | 69,252 | $276K |
Showing top 10 of 39 institutional holders of Sensus Healthcare Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 2.8%
- Days to cover
- 11.2
- Shares short
- 422,044
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SRTS short interestFrequently asked questions
What is the AI investment thesis for Sensus Healthcare Inc.?
Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological conditions, with a recent cash position of $15.2M as of 2026-06-30 and ongoing revenue generation from equipment sales.
Who is the CEO of Sensus Healthcare Inc.?
Mr. Joseph C. Sardano is the chief executive officer of Sensus Healthcare Inc. (SRTS).
Where is Sensus Healthcare Inc. headquartered?
Sensus Healthcare Inc. (SRTS) is headquartered in Boca Raton, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.